Treatment of advanced pancreatic cancer: From gemcitabine single agent to combinations and targeted therapy

Cancer Treatment Reviews

Volumn 35, Issue 4, 2009, Pages 335-339

  Rivera, Fernando ^a   López Tarruella, Sara ^a   Vega Villegas, Ma Eugenia ^a   Salcedo, Matilde ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AP 12009; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CISPLATIN; CURCUMIN; ERLOTINIB; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GEMCITABINE PLUS OXALIPLATIN; GEMOX; IRINOTECAN; MARIMASTAT; OXALIPLATIN; PEMETREXED; PLACEBO; PLATINUM COMPLEX; PROTEASOME INHIBITOR; SCATTER FACTOR RECEPTOR INHIBITOR; SOMATOMEDIN RECEPTOR INHIBITOR; TALABOSTAT; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA2 ANTIBODY; UNCLASSIFIED DRUG; VOLOCIXIMAB;

ADVANCED CANCER; BLOOD TOXICITY; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; REVIEW; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 67349117952     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.11.007     Document Type: Review

References (45)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Yeo T.P., Hruban R.H., Leach S.D., et al. Pancreatic cancer. Curr Probl Cancer 26 (2002) 176
3. Sultana A., Smith C.T., Cunningham D., Starling N., Neoptolemos J.P., and Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25 (2007) 2607-2615
4. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15 (1997) 2403-2413
5. Kindler H.L., Niedzwiecki D., Hollis D., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25 June 20 Suppl. (2007) 4508
6. Philip P.A., Benedetti J., Fenoglio-Preiser C., et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study. J Clin Oncol 25 June 20 Suppl. (2007) LBA4509
7. Vervenne W.B.J., Humblet Y., Gill S., et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol 26 May 20 Suppl. (2008) 4507
8. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (2007) 1960-1966
9. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with metastatic pancreatic cancer. An exploratory subset analysis. Annals Oncol 18 Suppl. 7 (2007) vii 14 [Abs O-0010]
10. Cunningham D., Chau I., Stocken D., et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Suppl. 3 (2005) 4 [Abst PS 11]
11. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25 (2007) 2212-2217
12. Bernhard J., Dietrich D., Scheithauer W., et al. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial - SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol 26 (2008) 3695-3701
13. Bria E., Milella M., Gelibter A., et al. Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials. Cancer 110 (2007) 525-533
14. Heinemann V., Boeck S., Hinke A., Labianca R., and Louvet C. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 8 (2008) 82
15. Banu E., Banu A., Fodor A., et al. Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging 24 (2007) 865-879
16. Xie D.R., Liang H.L., Wang Y., Guo S.S., and Yang Q. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol 12 (2006) 6973-6981
17. Tempero M., Plunkett W., Ruiz Van Haperen V., et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21 (2003) 3402-3408
18. Poplin E., Levy D.E., Berlin J., et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion[FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). J Clin Oncol 24 June 20 Suppl (2006) LBA4004
19. Xiong H.Q., Wolff R.A.H., Hess K.R., Varadhachary G.R., Blais J.C., and Abbruzzese J.L. A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer. J Clin Oncol 24 June 20 Suppl. (2006) 4119
20. Tsavaris N., Kosmas C., Skopelitis H., et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 23 (2005) 369-375
21. Oettle H., Pelzer U., Stieler J., et al. Oxaliplatin/folinic acid/5-fluorouracil [24 h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). J Clin Oncol 23 June 20 suppl. (2005) 4031
22. Pelzer U., Kubica K., Stieler J., et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26 May 20 Suppl. (2008) 4508
23. Moore M.J., da Cunha Santos S., Kamel-Reid S., et al. The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol 25 June 20 Suppl. (2007) 4521
24. Hasmi S., Black G., Bell D., et al. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival. J Clin Oncol 25 June 20 Suppl. (2007) 4606
25. Ko A.H., Scott J., Tempero M.A., and Park J.W. Detection and significance of circulating tumor cells (CTC) in patients with metastatic pancreatic cancer (PC) receiving systemic therapy. J Clin Oncol 25 June 20 Suppl. (2007) 4596
26. Mancuso A., Sacchetta S., Saletti P., et al. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second line chemotherapy: results of an Italian/Swiss multicenter survey. J Clin Oncol 25 June 20 Suppl. (2007) 4622
27. Ouchi K.F., Yanagisawa M., Sekiguchi F., and Tanaka Y. Antitumor activity of erlotinib in combination with capecitabine in human tumor xenograft models. Cancer Chemother Pharmacol 57 (2006) 693-702
28. Kulke M.H., Blaszkowsky L.S., Ryan D.P., et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 25 (2007) 4787-4792
29. Brell J.M., Matin K., Evans T., et al. Phase II study of gefitinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after first-line therapy. Final results. J Clin Oncol 25 June 20 Suppl. (2007) 4586
30. Spano J.P., Chodkiewicz C., Maurel J., et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371 (2008) 2101-2108
31. Oettle H., Seufferlein T., Schmid R., et al. Preliminary results of a phase I/II study in pancreatic carcinoma, malignant melanoma, and colorectal carcinoma with the TGF- β2 inhibitor AP 12009. J Clin Oncol 25 June 20 Suppl. (2007) 4607
32. Nugent F.W., Cunningham C., Barve M.A., et al. Phase 2 study of talabostat/gemcitabine in Stage IV pancreatic cancer. J Clin Oncol 25 June 20 Suppl. (2007) 4616
33. Dhillon N., Aggarwal B.B., Newman R.A., et al. Curcumin and pancreatic cancer: Phase II clinical trial experience. J Clin Oncol 25 June 20 Suppl. (2007) 4599
34. Bauer C., Dauer M., Saraj S., et al. Immunological and clinical response after vaccination therapy of pancreatic carcinoma patients with autologous, tumor-lysate pulsed dendritic cells: Results of a phase II-study. J Clin Oncol 25 June 20 Suppl. (2007) 4579
35. Evans T., Ramanathan R.K., Yazji S., et al. Final results from cohort 1 of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC). J Clin Oncol 25 June 20 Suppl. (2007) 4549
36. Berlin J., Catalano P., Thomas J., Kugler J., Haller D., and Benson A. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20 (2002) 3270-3275
37. Riess H., Helm A., Niedergethmann M., et al. A randomised, prospective, multicenter, phase iii trial of gemcitabine, 5-fluorouracil (5-fu), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol 23 June 20 Suppl. (2005) 4009
38. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24 (2006) 3946-3952
39. Louvet C., Labianca R., Hammel P., et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: final results of the GERCOR /GISCAD intergroup phase III. J Clin Oncol 22 June 15 Suppl. (2004) 4008
40. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., and Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87 (2002) 161-167
41. Van Cutsem E., van de Velde H., Karasek P., et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22 (2004) 1430-1438
42. Abou-Alfa G.K., Letourneau R., Harker G., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 24 (2006) 4441-4447
43. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22 (2004) 3776-3783
44. Oettle H., Richards D., Ramanathan R.K., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16 (2005) 1639-1645
45. Kindler H.L., Niedzwiecki D., Hollis D., et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 25 June 20 Suppl. (2007) 4508